Moderna Inc will have the ability to produce 500 million doses of its COVID-19 vaccine in 2021, Chief Government Officer Stéphane Bancel mentioned on Friday.

The corporate has submitted purposes in search of emergency use authorization in the US and the European Union after full outcomes from a late-stage examine confirmed the vaccine was 94.1% efficient with no severe security issues.

“For 500 million, I’m very comfy we’re gonna get there (2021),” Bancel mentioned on the Nasdaq Investor Convention.

He additionally mentioned the corporate would have the ability to preserve a premium value of $37 for its vaccine doses, though the premium is anticipated to fall to $25 for big-volume provides, such because the one to the U.S. authorities.

The Meals and Drug Administration is about to carry an advisory committee assembly on Dec. 17 to debate the corporate’s request for emergency authorization for its COVID-19 vaccine.

Bancel mentioned the corporate has seen renewed demand from many nations in search of further doses after it reported scientific knowledge.

moderna covid 19 vaccine
Moderna coronavirus-19 vaccine

Earlier on Friday, Moderna prolonged its contract with the Israeli well being ministry to produce a further 4 million doses of its COVID-19 vaccine candidate.

The corporate mentioned on Thursday it will provide as much as 125 million doses of the vaccine by the primary quarter of 2021.

Reporting by Mrinalika Roy and Trisha Roy in Bengaluru; Modifying by Anil D’Silva, Aditya Soni.